# Ainos, Inc.: Form 10-Q for the period ended Sep 30, 2016

- Company: [Ainos, Inc.](/companies/aimd.md) (CIK 1014763)
- Form: 10-Q
- Filed: 2016-11-21
- Accepted by EDGAR: Nov 21, 2016, 14:44 ET
- Period: 2016-09-30
- Accession: 0001014763-16-000040
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1014763/000101476316000040/form10q_09302016.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1014763/000101476316000040/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 9 months, 2016-01-01 to 2016-09-30 | $4.4k | us-gaap:Revenues |
| Cost of revenue | 9 months, 2016-01-01 to 2016-09-30 | $5.1k | us-gaap:CostOfRevenue |
| Gross profit | 9 months, 2016-01-01 to 2016-09-30 | −$700 | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2016-07-01 to 2016-09-30 | $178.5k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2016-01-01 to 2016-09-30 | $434.2k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2016-07-01 to 2016-09-30 | −$178.5k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2016-01-01 to 2016-09-30 | −$434.9k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2016-07-01 to 2016-09-30 | $798 | us-gaap:InterestExpense |
| Interest expense | 9 months, 2016-01-01 to 2016-09-30 | $2.3k | us-gaap:InterestExpense |
| Net income | 3 months, 2016-07-01 to 2016-09-30 | −$179.3k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2016-01-01 to 2016-09-30 | −$437.1k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-07-01 to 2016-09-30 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2016-01-01 to 2016-09-30 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2016-01-01 to 2016-09-30 | −$427.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2016-01-01 to 2016-09-30 | $47.7k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2016-09-30 | $176.4k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-09-30 | $281.5k | us-gaap:AssetsCurrent |
| Total assets | at 2016-09-30 | $442.0k | us-gaap:Assets |
| Current liabilities | at 2016-09-30 | $929.3k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-09-30 | $929.3k | us-gaap:Liabilities |
| Shareholders' equity | at 2016-09-30 | −$487.3k | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 13,593 characters.

*The following discussion should be read in conjunction with our financial statements and the notes thereto which appear elsewhere in this report. The results shown herein are not necessarily indicative of the results to be expected in any future periods.*

Forward-Looking Statements: Certain statements made throughout this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance, achievements, costs or expenses and may contain words such as "believe," "anticipate," "expect," "estimate," "project," "budget," or words or phrases of similar meaning. Forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from those projected in the forward-looking statements. Such risks and uncertainties are detailed from time to time in reports filed by the Company with the Securities and Exchange Commission, including Forms 8-K, 10-Q and 10-K and include among others the following: promulgation and implementation of regulations by the U.S. Food and Drug Administration ("FDA"); promulgation and implementation of regulations by foreign governmental instrumentalities with functions similar to those of the FDA; costs of research and development and trials, including without limitation, costs of clinical supplies, packaging and inserts, patient recruitment, trial monitoring, trial evaluation and publication; and possible difficulties in enrolling a sufficient number of qualified patients for certain clinical trials. The Company is also dependent upon a broad range of general economic and financial risks, such as possible increases in the costs of employing and/or retaining qualified personnel and consultants and possible inflation which might affect the Company's ability to remain within its budget forecasts. The principal uncertainties to which the Company is presently subject are its inability to ensure that the results of trials performed by the Company will be sufficiently favorable to ensure eventual regulatory approval for commercial sales, its inability to accurately budget at this time the possible costs associated with hiring and retaining of additional personnel, uncertainties regarding the terms and timing of one or more commercial partner agreements and its ability to continue as a going concern.

The risks cited here are not exhaustive. Other sections of this report may include additional factors which could adversely impact the Company's business and future operations. Moreover, the Company is engaged in a very competitive and rapidly changing industry.

New risk factors emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the Company's business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those projected in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual future events.

**Overview.** ABI has been (and is) engaged in the business of biopharmaceutical research and development. Its primary focus historically has been the development of low-dose, orally administered interferon. ABI holds or licenses various patents; it also is the developer of Maxisal®, a dietary supplement to treat dry-mouth symptoms.

Having successfully reorganized, the Company's goal continues to be the expansion of the reach of its research, development, and marketing of biopharmaceutical, biotechnical, health and life science related products. ABI will continue to leverage its core technology going forward by using its thirty years of scientific and clinical data to establish interferon-alpha lozenges as a therapeutic agent for conditions such as influenza, hepatitis C, and various causes of thrombocytopenia just to name a few. The Company is committed to expanding its business operations from the currently narrow focus to encompass a wide variety of licensing, partnerships, and development opportunities in the aforementioned sectors. This commitment extends not only to the U.S., but to Taiwan, China, and other Asian Countries.

ABI holds various patents and related intellectual property, which are described earlier in this document. The most significant asset is intellectual property consisting of three patents, one pending patent, and one trademark. One of the patents expires in less than two years and two of the patents expire in a range of three to five years. It is expected that the pending patent will be fully approved and issued by the end of 2016. These three patents and the single, soon-to-be-issued, pending patent employ the Company's core technology, which is the oral, low dosage use of (human) interferon. These patents will not have significant value unless commercialized, which will require adequate funding, time, effort, and expertise in biologics. As previously stated, ABI's sole source of human interferon discontinued production, which negatively impacted ABI's ability to obtain source product. The anticipated location and development time required for a new source of human interferon along with the requisite testing and FDA approval time could exceed the life span of all of the patents, and even if it does not, would leave relatively little time to derive revenues from the patent protections, prior to patent expiration. The third patent, a product promoting oral health, also is the victim of supply-chain interruption because the supplier of the raw material for the product (anhydrous crystalline maltose, or ***"ACM"***) has substantially increased its purchase price. The price increase and other actions have rendered the manufacture and sale of the product less attractive.

It is anticipated that ABI will attempt to monetize and commercialize its existing intellectual property, which would necessitate identification and acquisition of new source product (e.g., Interferon), conducting new trials, and additional protection of intellectual property. It is estimated this may require additional funding (including general administrative cost and professional fees) of between $500,000 and $800,000. Similarly, ABI may explore the acquisition and development of new product lines. The cost to commercialize any such development could likely require a similar funding level, resulting in aggregate funding requirements between $1 million and $1.6 million. These activities, even if undertaken, would not be expected to produce meaningful revenue before the last calendar quarter of 2017, or possibly later.

### Pending Litigation

To the best of management's knowledge, the Company does not believe that there is any pending litigation against ABI.

### Tax Consequences

**ABI's** most recent tax return and financial statements reflect tax attributes that may or may not be obtainable. Some of these tax attributes (*e.g.*, net operating loss carry forwards (***"NOL"***), if any) are for the benefit of ABI. According to the Company's most recent federal income tax return, the face amount of the NOL was $21,683,436. The Company's NOL derived from the emergence from Chapter 11 Bankruptcy that closed on February 13, 2015. ABI has not independently verified or otherwise confirmed the favorable nature of such tax attributes or the extent to which any of the NOL can still be used. It is the Company's belief that obtaining the value of such tax attributes may be difficult and directly dependent upon many factors outside of our control, including, but not limited to, changes in the legal and regulatory framework and the operational and corporate structure of ABI and shareholders, or sales or transfers of stock by or among shareholders. For example, if ABI has experienced a change of control as defined in the relevant provisions of the IRC,1 the use of any existing tax attributes could be severely limited. ABI does not believe the reorganization has or will impair any tax attributes; however, obtaining value from the tax attributes is a function of the Company's return to profitable operations and the timeframe of that return. While we believe it is possible, there is no assurance that ABI will return to profitability in the future.

### Results of Operations for Three Months Ended September 30, 2016 and 2015:

Revenues. During the three months ended September 30, 2016, and September 30, 2015 there were no sales of ginseng samples, dietary supplements or ACM.

Research and Development Expenses. Research and development expenses have not been incurred for the three months ended September 30, 2016, and September 30, 2015.

Selling, General and Administrative Expenses. Selling, general and administrative expenses of $178,470 were incurred for the three months ended September 30, 2016, compared to $113,552 for the three months ended September 30, 2015, an increase of $64,918 (57%). This increase is contributed to additional professional fees, ginseng expense, postage/shipping expenses and overall increased activity in 2016.

Operating Loss. In the three months ended September 30, 2016, the Company's operating loss was $178,470 compared to an operating loss for the three months ended September 30, 2015 of $113,552, a $64,918 increase. This increase is contributed to additional professional fees, ginseng expense, postage/shipping expenses and overall increased activity in 2016.

1 *See* 26 U.S.C. § 382 (known as Section 382 of the IRC) and related regulations.

Interest Expense. During the three months ended September 30, 2016, interest expense was $798, compared to $596 for the three months ended September 30, 2015. The interest expense recognized in the three months ended September 30, 2016 is mostly due to accrued interest for our convertible debt notes with Stephen Chen.

Net Loss. In the three months ended September 30, 2016, the Company's net loss was $179,268 compared to a net loss for the three months ended September 30, 2015, of $114,148 an $65,120 (57%) increase. This increase was mainly due to additional professional fees, ginseng expense, postage/shipping expense, and overall increased activity in 2016.

### Results of Operations for the Nine Months Ended September 30, 2016 and 2015:

Revenues. During the nine months ended September 30, 2016 and September 30, 2015 there were no sales of dietary supplements, or ACM. During the nine months ended September 30, 2016, there were $4,400 in sales of ginseng samples, a potential source of revenue.

Research and Development Expenses. Research and development expenses have not been incurred for the nine months ended September 30, 2016, and September 30, 2015.

Selling, General and Administrative Expenses. Selling, general and administrative expenses of $434,176 were incurred for the nine months ended September 30, 2016, compared to $327,473 for the nine months ended September 30, 2015, an increase of $106,703 (33%). This increase is mostly due to higher professional fees, project expense and travel related costs.

Net Operating Loss. In the nine months ended September 30, 2016, the Company's operating loss was $434,876 compared to an operating loss for the nine months ended September 30, 2015 of $327,473, a $107,403 (33%) increase.

Interest Expense. During the nine months ended September 30, 2016, interest expense was $2,257, compared to $1,614 for the nine months ended September 30, 2015, an increase of $643 (40%). The interest expense recognized in the nine months ended September 30, 2016 is mostly due to accrued interest for our convertible debt loans with Stephen Chen and interest paid associated with our D&O insurance policy payment.

Net Loss. In the nine months ended September 30, 2016, the Company's net loss was $437,133 compared to a net loss for the nine months ended September 30, 2015 of $329,087, a $108,046 (33%) increase.

### Liquidity and Capital Resources

At September 30, 2016, we had available cash of $176,357 whereas we had a cash position of $21,138 as of December 31, 2015. The Company had a working capital deficit of $362,167 at the end of September 30, 2015. For 2016, the working capital deficit was $647,778. Historically the burn rate was between $50,000 and $60,000 per month. It is difficult to estimate the burn rate at this point insomuch as the new business lines and revenue streams are still being developed. One of the Company's main goals is to return to the status of a going concern by having reduced operating losses and subsequently becoming profitable. As indicated throughout this document, two other major goals of ABI are to (1) leverage the core technology, low-dose oral interferon, and (2) diversify Company operations to incorporate additional lines of business which will extend the reach of ABI into additional economic sectors such as biotech / bio-pharmaceutical / health care products and life sciences business. The investor base has indicated the willingness to assist in future financing of operations as ABI seeks to monetize its existing (and potentially newly developed) intellectual property. ABI estimates its post-reorganization financing needs to be between $1,000,000 and $1,600,000.

There can be no assurance that we will be successful in our efforts to make the Company profitable. If those efforts are not successful, we will be forced to cease operations.

## Controls and procedures

As filed, 1,747 characters.

#### Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 under the Exchange Act, we have carried out an evaluation of the effectiveness of the design and operation of our company's disclosure controls and procedures as of the end of the period covered by this quarterly report, being September 30, 2016. This evaluation was carried out under the supervision and with the participation of our company's management, including our company's chairman of the board and chief executive officer, Dr. Stephen T. Chen and chief financial officer, Bernard Cohen. Our company's disclosure controls and procedures are effective as at the end of the period covered by this report.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our company's reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our company's reports filed under the Exchange Act is accumulated and communicated to management, including our company's president and chief executive officer as appropriate, to allow timely decisions regarding required disclosure.

#### Changes in Internal Controls Over Financial Reporting

There were no changes in our internal controls over financial reporting that occurred during the quarterly period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed Nov 21, 2016.
Source: SEC EDGAR, the filing index for accession 0001014763-16-000040. Last ingested by Listed: Nov 11, 2026, 00:28 ET. No prices; not investment advice.
